california dmhc glp-1 coverage exclusion allowed Patients on Medi-Cal who are Already Prescribed and Take Zepbound: 2025-2026 Budget Changes that Eliminate of Drugs for Weight Loss as that Comes Up Against Existing California Law GLP-1 Coverage Debate Comes Down
Description
These products were distributed to patients

By April 1, that number increased to 1,685, reflecting 164 new filings in just one month
Semaglutide (Ozempic/Wegovy) is a GLP-1 receptor agonist, while tirzepatide (Mounjaro/Zepbound) is a dual GIP/GLP-1 receptor agonist
CDSCO Approved Drugs / Vaccines / r-DNA / Blood Product [Internet]

What patients tend to value Direct access to a licensed provider Clear dosing instructions Lab review when medically appropriate Easy refill coordination Shipment from licensed U.S

However, actual out-of-pocket costs depend heavily on your insurance coverage and available savings programs
